DLCIG
CERE

D.L. Carlson Investment Group’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

D.L. Carlson Investment Group’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,500
Closed -$322K – 146
2023
Q4 		$322K Buy
+7,500
New +$216K 0.07% 119

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

D.L. Carlson Investment Group's CERE Position: Q1 2024 in Review

D.L. Carlson Investment Group sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2024, closing a stake of 7,500 shares — an estimated $322K sold.

D.L. Carlson Investment Group first reported a position in CERE in Q4 2023 and held it in 1 quarter. The position peaked at $322K in Q4 2023. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

  • D.L. Carlson Investment Group reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • D.L. Carlson Investment Group sold 7,500 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $322K.
  • D.L. Carlson Investment Group first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2023 and held it in 1 quarter.
  • D.L. Carlson Investment Group's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $322K in Q4 2023.
  • 210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on D.L. Carlson Investment Group's 13F filing for Q1 2024, filed 14 May 2024.